The role of Chemokines in Thyroid Carcinoma

Authors: Sharinie Yapa¹ MRCS (ENT), Omar Mulla¹ (MRCS) (DOHNS), Victoria Green² (PhD),
James England¹ FRCS (ORL-HNS), John Greenman² (PhD),

¹Department of Otolaryngology and Head and Neck Surgery, Castle Hill Hospital, Hull, HU16 5JQ, United Kingdom. ²School of Biological, Biomedical and Environmental Sciences, University of Hull, Cottingham Road, Hull, HU16 7RX, United Kingdom.

Contact information of authors:

Sharinie Yapa: sharinie@gmail.com, Tel: +44 (0)7935926964

Omar Mulla: omarmulla22@gmail.com, Tel: +44 (0)7790848009

Victoria Green: v.l.green@hull.ac.uk, Tel: +44 (0)1482 465502

James England: james.england@hey.nhs.uk, Tel: +44 (0)1482 624781

John Greenman: j.greenman@hull.ac.uk, Tel: +44 (0)1482 466032

Main corresponding author: Miss Sharinie Yapa; sharinie@gmail.com

The Role of Chemokines in Thyroid Carcinoma

Key words: chemokine, thyroid carcinoma, leukocytes, inflammation, metastasis
Abstract:

The global incidence of thyroid cancer is increasing and metastatic spread to lymph nodes is common in papillary thyroid carcinoma. The metastatic course of thyroid carcinoma is an intricate process involving invasion, angiogenesis, cell trafficking, extravasation, organ specific homing and growth. A key aspect in this process involves a multitude of interactions between chemokines and their receptors. Chemokines are a group of small proteins, which act to elicit normal physiological and immune responses principally through recruitment of specific cell populations to the site of infection or malignancy. Thyroid cancer cells, like other tumors, possess the ability to corrupt the chemokine system to their advantage by altering cell movement into the tumor microenvironment and affecting all aspects of thyroid cancer progression.
Introduction:

Thyroid carcinoma remains the most common type of endocrine-related cancer with an estimated 62,450 new cases worldwide in 2015 and represents approximately 3.8% of all new cancer cases overall (1). Although the majority of thyroid cancers are highly treatable, with a five-year survival of the most common types such as papillary and follicular being close to 100% for patients with stage I and II tumors (1), papillary thyroid carcinoma (PTC) in particular is renowned for early metastasis to lymph nodes. The metastatic potential of these cancers is governed in part by the interaction and influence of thyroid malignant cells with the chemokine system.

Chemokines (chemo attractant cytokines) are a small conglomerate of specialized proteins, which act together through their cell surface receptors to coordinate a series of actions. The secretion of chemokines by particular cell types promotes homeostasis, organ development and immune responses by directing cells to specific locations throughout the body (2). Due to the varied and dynamic expression of multiple receptors on the surface of leukocytes, endothelial and tumor cells, chemokines recruit specific cell populations as required.

There are four major groups of chemokines: CXC, CC, CXC3 and C (Figure 1) whose nomenclature varies depending on the position of the conserved cysteine residues with the corresponding receptors binding to the ligand (2). Chemokines and their receptors are generally known by their systematic names consisting of the family of chemokine followed by the letter “L” for “Ligand” or “R” for “receptor”, with a number indicating their order of discovery. For example, the chemokine originally named Stromal derived factor 1 is now termed CXC chemokine ligand 12, i.e. CXCL12, and its associated receptor is CXCR4 (3). To date there have been fifty chemokines identified with eighteen chemokine receptors described (4) (Table 1). There are more chemokines than receptors, meaning that many cell surface receptors bind to multiple chemokines and vice versa. This type of system is common within biology and is said to possess redundancy, which means that key pathways are not solely dependent on single factors (5),(6).
Chemokine receptors are all structurally related and are members of the seven transmembrane G protein-coupled cell surface receptor family (Figure 2). Chemokines are highly soluble secretory proteins that either remain free in solution or become immobilized on cell surfaces or more generally in the extracellular matrix (ECM), establishing concentration gradients (7), which facilitates direct movement, or chemotaxis, of cells expressing appropriate receptors to the specific target area (8). The chemokine secretion profile is highly dynamic and as a tumor develops the amount and nature of the profile will change. Chemokines are not only sub-divided in terms of the receptors they interact with but also their principal roles, i.e. inflammatory, (2),(9),(10),(11) (Figure 3). To date, it is the inflammatory, homeostatic and atypical chemokine receptors that have been reported to be important with respect to the tumor microenvironment.

Malignant cells have found a way to subvert the chemokine system to their advantage via chemotaxis, thereby influencing cell trafficking within the tumor microenvironment (5), (12). These “corrupted” chemokines are secreted from both primary tumors and metastatic sites (6). They behave like growth factors (13) contributing to angiogenesis (14), immunosuppression and proliferation of fibroblast stroma, which in turn increases the survival of tumor cells, enhancing tumor growth and metastatic potential (5),(6). This is because malignant cells gain functional chemokine receptors that are often not found on their normal counterparts, and like leukocytes, they can respond to chemokine gradients at sites of metastasis (15), (16).

The malignant thyroid microenvironment:

It is widely acknowledged that there is a strong relationship between cancer and inflammation. This has been observed since 1863 when Virchow observed leucocytes in neoplastic tissue and hypothesized that chronic inflammation could contribute to the tumorigenic process (17). It is estimated that about 20% of all tumors arise from conditions of chronic inflammation (17) including thyroid carcinoma from chronic thyroiditis (18). The inflammatory microenvironment of thyroid carcinoma is complex, consisting mainly of leucocytes such as macrophages, T lymphocytes, dendritic, mast, and natural killer (NK)
cells which circulate amongst the tumor cells and supporting stroma (19). These leucocytes can account for up to 50% of the tumor mass with the predominant subset being macrophages (20). Chemokines shown to exist at relatively high levels within the thyroid tumor mass also results in de novo chemokine receptor expression on the tumor cells and immune cells (21). Production of inflammatory mediators within the thyroid microenvironment are CXCL8 (21-24) and CXCL20 (25,26,27); these are produced by both immune cells and tumor cells (28-32) and CXCR4 (28-32) and CCR7 (28,30,32,33).

The majority of thyroid tumor literature has focused on detecting chemokines in the tumor mass and highlighting how these may work through the tumor associated macrophages, with a relatively small number of studies detailing the role of chemokines in the attraction of other immune cells, most probably because the latter studies are more complicated and expensive. The aim of this review is to comprehensively review the current knowledge of chemokines and their receptors in thyroid carcinoma.
Method:

A comprehensive literature search was performed using Pubmed, Google Scholar and MEDLINE databases between the years 1996 to 2016 with the following key words: 1.) Chemokine and thyroid carcinoma; 2.) leukocyte and thyroid carcinoma; 3.) chemokine and metastasis in thyroid carcinoma; and 4.) inflammation and thyroid carcinoma. Four separate searches were performed in each database. A total of 26,200 studies were found, with 141 being relevant to thyroid carcinoma. No restrictions on language were used. Unpublished reports, including dissertations and conference abstracts were not considered.

Inclusion and exclusion criteria:

All titles and abstracts of the retrieved articles were reviewed. Studies were included if they met the following criteria: 1. Studies investigating chemokines and oncogenic changes in thyroid carcinoma; 2. Studies looking at chemokines, inflammation and tumor associated leukocytes; 3. CK induced metastatic potential of thyroid carcinoma; and 4. The therapeutic potential of chemokines in thyroid carcinoma. The major reasons for exclusion were due to the studies not being specific to chemokines and thyroid carcinoma.

Pro-tumorigenic chemokines and associated cells in thyroid carcinoma:

Tumor progression and migration: CXCL8 and CCL20

One of the more abundantly expressed chemokines by thyroid carcinoma cells is CXCL8. This was the first chemokine shown to be secreted by thyrocytes (24) and there is evidence to support a role for CXCL8 and its interaction with receptors CXCR1 and CXCR2 in regulating cell migration, tumor growth, progression, metastatic spread and tumor-associated angiogenesis in various cancers (8), (21), (22). Both Yoshida et al. (21) and Weetman et al. (22) observed production of CXCL8 as a chemotactic factor for neutrophils
in the supernatants of primary cultures of normal thyroid cells. Since then, Basolo et al. (23) demonstrated that papillary and anaplastic cell lines release large amounts of CXCL8. Kobawala et al. (24) looked at serum levels of CXCL8 in 88 patients with thyroid diseases: 21 with goiter, 16 with autoimmune thyroid disease, and 32 with differentiated thyroid carcinoma (DTC). Serum CXCL8 levels were significantly higher in DTC patients of various histological subtypes compared with autoimmune thyroid disease patients. CXCL8 levels were also similar in healthy controls and early stage thyroid carcinoma patients, but were significantly increased in patients with advanced thyroid carcinoma.

CCL20 is another prominent chemokine involved in thyroid carcinoma and is the only ligand that activates receptor CCR6 (25). Increased levels of CCL20 are seen in many forms of cancer such as colorectal (34), pancreatic (35), lung (36) and hepatocellular carcinoma (37) and closely correlate to tumor growth (38), metastasis (37) and overall poor prognosis (34-37). Zeng et al. (26) demonstrated that CCR6 was overexpressed by thyroid cancer cell lines and also that activation of CCR6 by CCL20 promoted invasion and migration whilst blocking of the receptor reversed the effect. They also observed that CCL20/ CCR6 interaction in thyroid carcinoma enhanced tumor growth and invasive capabilities.

**Tumor neovascularization and growth: Endothelial cells and CXC chemokines**

It is well known that neovascularization is crucial for tumor growth, progression and metastasis and some chemokines are known to be involved in this process (39). The CXC chemokines can be divided up into two groups, those that have the ELR positive (ELR+) motif and those, which are ELR negative (ELR-). The ELR+ is an important structural domain for angiogenic activity, because it determines the specificity of the CK binding to its cognate receptor (39). The ELR+ group includes chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 (39) that directly promote migration and proliferation of endothelial cells and eventually neovascularization, mainly by interacting with receptor CXCR2 and not CXCR1 (40). The ELR- groups have anti-angiogenic properties and consist of CXCL4, CXCL9, CXCL10 and CXCL11 (40). Furthermore the Duffy antigen has been shown to
suppress the angiogenic effects of the ELR+ CXC chemokines in thyroid cancer as it can sequester these without eliciting any intracellular signals (27), thus the balance between pro- and anti-angiogenic CK determines the degree of tumor neovascularization.

**Tumor growth, invasion and survival**

Tumor associated macrophages (TAM):

The review of the literature highlighted numerous studies looking at the relationship between thyroid carcinoma and tumor associated macrophages (TAM). TAM are derived from circulating monocytes and are attracted to the tumor microenvironment by a number of CC and CXC chemokines such as CCL2, CCL5, CCL7, CCL8, CCL12 (20), CXCL8 (41) and CXCL16 (42) via their surface expression of receptors CXCR1, CXCR2 (41) and CXCR6 (42).

TAM can differentiate into either M1 type (phagocytic, anti-tumorigenic) or M2 type (proliferative, pro-tumorigenic) cells, however within the thyroid tumor microenvironment, TAM generally express M2 polarization (2) and have well documented tumor promoting activities, i.e. cancer initiation and progression and in general a high TAM count is indicative of poor prognosis (43-46). This is largely due to TAM promoting tumor progression by producing factors such as VEGF, fibroblast growth factor and suppressing anti-tumor immunity (47) (Figure 4).

In 2013 Weiyuan et. al. (41) conducted experiments both in vitro and in vivo to evaluate whether the secretion of CXCL8 by TAM promoted the metastatic potential of PTC. In vitro, they analyzed TAM conditioned medium and its propensity to promote PTC cell invasion. In vivo, they injected mice with both PTC cells and CXCL8 and after 40 days the metastatic lesions were counted and measured. The results indicated that TAM could initiate and promote PTC by releasing CXCL8 and an increased density of TAM correlated with increased lymph node metastases. TAM density in the tumor core was associated with progressive PTC features, and a medium enriched with TAM enhanced the invasion of PTC. CXCL8 was identified as the most abundant chemokine in PTC derived TAM. Blocking
it with anti-CXCL8 neutralizing antibody significantly decreased PTC metastases and exogenous CXCL8 enhanced PTC metastases in vivo (41). It was also noted that CXCR1/2 receptors (which CXCL8 binds to) were only present in tumor tissue, and not found in normal healthy thyroid tissue. Therefore TAM may facilitate PTC cell metastases through CXCL8 and its paracrine interaction with CXCR1/2 (41).

Furthermore, a recent study by Cho et al. in 2016 (42) found that CXCR6 expression positively correlated with lymph node metastasis and CXCL16 signaling mediated macrophage enhanced PTC tumor cell invasion and also changed the macrophage phenotypes into M2-macrophages in the PTC environment.

A study of 398 patients with DTC and 132 patients with benign thyroid tissue indicated that TAM were found more frequently in aggressive cases with metastasis at diagnosis, but conversely macrophage infiltration was also associated with improved disease free survival (48). This paradoxical result was attributed to three reasons; i.) Varying microenvironments in different histological subsets ii.) TAM modulation of the TME by secretion of a rich repertoire of chemokines and growth factors that exert paracrine effects on tumor cells to facilitate progression, and iii.) TAM phagocytic activity, which could also limit tumor progression (49). This was further confirmed by Fiumara et al. (50), in a study of 121 well differentiated thyroid carcinoma specimens demonstrating that tumors with TAM in situ showed evidence of active neoplastic cell phagocytosis which was in turn positively correlated with infiltration of lymphocytes and dendritic cells, and negatively correlated with vascular invasion. It is possible that these different results are also related to different populations (50).

**Mast cells:**

Mast cells are an important constituent of the thyroid carcinoma microenvironment. Recent studies indicate that PTC induces mast cell activation and chemoattraction via secretion of CXCL1, CXCL10 and CXCL8 (51). Mast cell numbers are elevated in PTC compared to normal thyroid tissue, and their increased density correlates with a poor prognosis (51). Further experiments using mast cell lines showed that PTC culture medium
induced mast cell activation and chemo-atraction, thereby increasing vascularity, proliferation, survival, invasiveness and DNA synthesis of cancer cells and inhibiting apoptosis. These actions were mediated by histamine, CXCL1 and CXCL10; therefore, targeting these pathways may be of therapeutic benefit in future.

**Tumor invasion, metastasis and aggression**

**CCR7:**

CCR7 is present in benign thyroid tissue, papillary and medullary thyroid carcinomas (30). It binds to CCL21 which causes proliferation and migration of tumor cells (30), (33) and also plays a critical role in lymphocyte and dendritic cell trafficking into lymph nodes, which are the preferential sites of metastasis of PTC and medullary thyroid carcinoma (MTC) (33).

It is well established that poorly differentiated thyroid carcinoma preferentially metastasize to bone, lung, liver and brain whereas DTC metastasize to lymph nodes. PTC has two variants; follicular variant of PTC and classic PTC of which the latter has a higher propensity for lymph node metastasis. Sancho *et al.* (33) analyzed CCR7 expression in 46 normal thyroid tissue and thyroid carcinoma specimens. The expression of CCR7 was higher in classic PTC and MTC, which are both prone to lymph node metastasis compared to follicular variants and was absent in healthy thyroid tissue. As only a subset of PTC develop lymph node metastasis, this would support the concept that CCR7 signaling is not only involved in proliferation and migration but also may play a key role during the tumor initiation phase. CCR7 expression is regulated *in vitro* by extracellular conditions, namely nutrient deficiency, which may mimic areas inside tumors with high proliferation rates (33) and its activation is significantly increased after 48 and 72 hr stimulation with CCL21 suggesting that the lymph nodes, where CCL21 is abundant, provide favorable conditions for the proliferation of metastatic thyroid cells once they migrate and arrest at these secondary sites.
CXCR4:

CXCR4 is the most widely expressed chemokine receptor in malignant cells (12), (19), (52) and plays a crucial role in migration, growth and metastasis (30), (53), (54) upon interaction with the ligand CXCL12. The binding of CXCL12 to CXCR4 has been shown to promote metastasis and survival in numerous human tumors including lung (55 – 56), breast (57), prostate (58) and colon (59). CXCR4 is not expressed at appreciable levels by normal thyrocytes, however it is up-regulated in normal thyrocytes transformed by the RET oncogene which subsequently increased proliferation, survival and migration of these cells in vitro (28), (31). Wagner et al. (30) conducted in vitro experiments looking at the expression of CXCR4 and CXCL12 on 88 samples of PTC using immunohistochemistry. Staining was matched with clinicopathological features, and revealed that high intensity staining for CXCR4 expression by the malignant cells was associated with larger tumor size and tumor aggression. These findings suggest that tumor cells may stimulate their own growth and invasion via an autocrine signaling mechanism (30).

Gonzalez et al. (32) found increased expression of CXCR4 and CCR3 in PTC compared to the control thyroid tissue indicating that these two receptors could be potential markers for PTC (32). In addition, increased CXCR4 correlated with lymph node metastases and extra-nodal extension in the classical variant of PTC suggesting that great expression of CXCR4 could be a factor contributing to aggressive tumors and negative prognosis (60-61).

Hwang et al. (29) demonstrated increased expression of CXCR4 on anaplastic thyroid carcinoma (ATC) cell lines compared to that of normal thyroid cells, and CXCL12 increased migration but not proliferation of ATC cells. The CXCL12/CXCR4 activation caused stimulation of ERK1/ERK2 (intracellular pathways designated to influence cell proliferation) and inhibiting these pathways by neutralizing them with anti-CXCR4 significantly decreased ATC cell migration.
CXCR7/CXCL12:

CXCR7 is a receptor for CXCL12, which is expressed in many cancer cell lines. It is produced by human thyrocytes (29) and is involved in cell migration and metastasis (62). Zhen et al. (62) showed, by immunohistochemistry, higher expressions of both CXCL12 and CXCR7 in PTC compared to benign tissue (non-malignant tissue 2 cm from the edge of the cancer specimen; n=79) and these expression patterns correlated significantly with lymph node metastasis. Additional work by others showed that down-regulation of CXCR7 in PTC suppressed cell growth, invasion and induced S-phase arrest as well as promoting apoptosis, indicating that it could be a promising target for therapeutic intervention (2).

CXCR1:

CXCR1 is one of two high affinity CXC chemokine receptors for CXCL8 and it is a major mediator of immune and inflammatory responses in tumor growth. It routinely induces chemotaxis of leukocytes and tumor cells. Tang et al. (63) looked at the expression of CXCR1 using IHC in 129 PTC, 61 nodular hyperplasia and 118 normal thyroid specimens, and found significantly higher expression in PTC specimens. Furthermore, CXCR1 expression was correlated with increased incidence of lymph node spread and has been suggested as a potential tool for predicting this risk in the future, but additional confirmatory studies are required.

A schematic diagram showing the pro-tumorigenic chemokines and their receptors in the thyroid tumor microenvironment is shown in Figure 5.
Anti-tumorigenic chemokines and associated cells in thyroid carcinoma:

**Decreased cell growth and increased apoptosis: CXCL10 and NK cells**

NK are lymphocytes, which can kill a broad range of tumor cells and are also found in the tumor mass (64). NK cells migrate to inflamed tissue including tumor sites and lymph nodes in response to signaling through chemokine receptors CCR1, CCR2, CXCR3 and CX3R1 (65). Gogaldi et al. (66) investigated NK infiltration in 65 patients with PTC and 25 patients with thyroid nodular goiter (NG) and found a significantly increased number of NK cells in the PTC samples, and demonstrated an inverse correlation between NK infiltration in advanced stages of the disease suggesting that the changes in the malignant TME could render NK cells redundant (66). Furthermore, a recent study in 2014 by Wenneberg et al. (67) demonstrated that ATC cell lines are sensitive to lysis by CXCR3 positive NK cells.

CXCL10, which binds to CXCR3, is up-regulated in PTC, (68-70) and its secretion is increased tenfold by induction with interferon gamma (IFNγ) and TNF alpha (TNFα) in PTC compared to normal thyroid follicular cells (TFC) (71). CXCL10 is involved in chemotaxis, induction of apoptosis, regulation of cell growth and mediation of angiostatic effects (72), mediating its effects in T cells, macrophages or NK cells (73-74). In 2012, Antonelli et al. (75) compared the expression of CXCL10 in ATC and normal thyroid follicular cell lines (TFC). They demonstrated that only ATC but not TFC produced CXCL10 under basal conditions; however, IFNγ stimulated secretion of CXCL10 in both cell lines in a dose dependent fashion. IFNγ and TNFα induced a synergistic but variable release of CXCL10 in different ATC samples; however the effect was more reproducible in the TFC biopsies.

**Angiostasis, decreased metastasis and recurrence, improved prognosis: DARC/ Duffy Antigen and lymphocytes**

Duffy or DARC (Duffy Antigen Receptor for Chemokines) is a glycosylated membrane protein which acts as a decoy by scavenging and binding to angiogenic chemokines such as CCL2 and CXCL8 (CK bearing the ELR+ motif) (76-77). Previous studies of DARC function in
breast (78-79), lung (80), and laryngeal cancer (81) have associated a DARC over-expression with better prognosis, decreased metastatic potential, and inhibition of tumor-associated neovascularization.

Latini et al. (76) demonstrated using immunohistochemistry decreased DARC expression in malignant thyroid tissue compared to that of benign origin. Diminished DARC expression in malignant samples also correlated with increased tumor size and lymphocyte infiltrate. There was no significant link between DARC and metastasis probably due to the propensity of PTC to metastasize via lymphatics rather than blood. It was concluded that larger tumors with decreased DARC expression may present more chemokines to the TME; this in turn could foster increased vascularization and tumor growth. This study clearly indicates that expression of these atypical CK receptors may be a key step in arresting tumor development however further research needs to be done to confirm this.

Lymphocytes are frequently found within and surrounding thyroid tumors (82-83). Their recruitment and trafficking is controlled by CC and CXC chemokines, particularly CXCR3 and associated ligands CXCL9 and CXCL10 (84). As cytotoxic T lymphocytes (CTL) can recognize tumor-associated antigens, they may confer some protection against the malignant process by attacking tumor cells (85), however as mentioned previously it is the balance between the type of cells present which will ultimately determine the nature of the TME. In 2011 Villagein et al. (86) investigated 157 patients with thyroid carcinomas and classified them by the degree of lymphocytic infiltration, i.e. diffuse, peri-tumoral and absent. After a mean follow-up period of eight years, significantly higher recurrence occurred in the group with absent lymphocytic infiltration, suggesting that presence of lymphocytes in the TME may be associated with a more favorable prognosis in patients with DTC, thus confirming previous similar studies done by Matsubayashi et al. (1995) (87), Gupta et al. (2001) (88), and Modi et al. (2003) (82).

Oncogenic changes inducing a pro-inflammatory response in thyroid carcinoma:

In PTC, genomic rearrangement and activating point mutations create dominantly transforming oncogenes the most common, and best studied being, RET/PTC1 (89-90) and
V600E in the BRAF gene (91), which both contribute to the induction of a pro-tumorigenic inflammatory microenvironment. RET is a proto-oncogene encoding for a tyrosine kinase receptor.

The RET/PTC1 oncogene has been shown to induce the expression of a pro-inflammatory program which includes the up-regulation of various chemokines including CCL2, CCL20, CXCL8, CXCL1, CXCL10 and CXCL12, (28), (68), (92) and the chemokine receptor CXCR4 (28), (68) along with other pro-inflammatory cytokines and enzymes. Mantonavi et al. (6), (19) postulated that rearrangement of the RET tyrosine kinase (RET/PTC) in thyrocytes represents a frequent, early, causative and sufficient genetic event in the pathogenesis of PTC (6). CXCL8 was also shown to be associated with angiogenesis and induction of the chemokine receptor CXCR4 on transformed thyrocytes. Furthermore, there was an abundance of key elements of the RET/PTC activated program in biopsy specimens and it was noted that patients with lymph node metastasis had higher levels of inflammatory molecules in their primary tumors.

Melillo et al. (68) demonstrated that activation of the RAS and BRAF/ERK pathways were also able to induce up-regulation of chemokines which contribute to neoplastic proliferation, survival and migration. Inflammation-related genes were further investigated by Muzza et al. (93) in a large series of PTC, divided into two groups according to the presence or absence of tumor-associated thyroiditis. RET/PTC changes were more abundant in patients with both PTC and thyroiditis whereas BRAF V600E was significantly more common in patients with PTC without thyroiditis. Fugazzola et al. (17) demonstrated that expression of chemokines CCL20 and CXCL8 was enhanced either in BRAF V600 or RET/PCT tumors compared to controls. Interestingly, thyroiditis specimens displayed the same levels of expression of CCL20 and CXCL8 compared to normal healthy thyroid tissue, suggesting that these chemokines could be associated with tumor-related inflammation rather than a primary autoimmune process. Torregrossa et al. (94) retrospectively evaluated CXCR4 expression in 200 PTC and compared clinicopathological features: type of PTC, degree of infiltration, cancer stage, presence of lymphoid thyroiditis, and mutation status of the \textit{BRAF} gene. They reported that raised CXCR4 expression was strongly correlated with the V600E BRAF mutation and, in combination, these factors were
associated with local aggressiveness of neoplastic cells. This could induce and promote a more aggressive phenotype in PTC thereby increasing tumor spread outside the thyroid gland.

**Chemokines and their receptors as potential screening tools and therapeutic targets in thyroid carcinoma**

Enhancing anti-tumorigenic chemokine pathways and tumor-mediated immunity:

As TAM are the most predominant leucocytes in tumors (20) and can promote tumor progression by inducing angiogenesis (43-46), blockade of common TAM associated chemokines such as CCL2, CXCL8 and their associated receptors could be a potential target for therapy. Migration of dendritic cells (DC) to lymph nodes is mediated by CCL19 and CCL21 via CCR7 (8). Although there are no studies demonstrating the role of dendritic cells and their associated chemokines in thyroid cancer, injection of CCL21 into mice with bilateral multifocal lung adenocarcinoma showed increased lymphocytes and dendritic cells at the tumor site and reduction in tumor burden, which enhanced survival (95). Therefore, further research into the possibility of therapies based on dendritic cells for thyroid carcinoma may be warranted. Neovascularization is also key for tumor growth, progression and metastasis (96), and targeting the ELR+ CXC chemokines may arrest tumorogenesis (8). Alternatively, the actions of ELR+ chemokines can be countered by addition of ELR- chemokines which inhibit angiogenesis (8).

Promoting oncogenic cellular senescence:

*Oncogenic cellular senescence, or oncogene induced senescence* (OIS) is defined as a stable and long term loss of proliferative capacity, despite continued viability and metabolic activity (97). In 2012, Weyemi et al. (98) first described RAS-induced senescence in thyroid cells by transducing human thyrocytes with an expression vector carrying cDNA for H-
RasV12. The expression of the mutated RAS induced DNA damage responses by triggering generation of reactive oxygen species, which are critical for promoting OIS. OIS acts as a protective mechanism against oncogenic transformation by suppressing unscheduled proliferation of any neoplastic cells (99).

BRAF mutations, most commonly V600E as mentioned above, are found in about 40% of PTC and play an important role in tumor initiation and progression. BRAF also downregulates the expression of genes involved in thyroid hormone synthesis and promotes de-differentiation in PTC (100, 101). In PTC, the frequency of malignancy increases as levels of TSH increase (102, 103). In 2016 Zou et al. (104) conducted experiments looking at the effects of BRAF V600E-induced PTC which were transplanted into mice with both normal TSH levels (nude mice group) and mice with elevated TSH levels (TPO transgenic BRAF mice). The results showed heavy lymphocytic and macrophagic infiltration with regression of transplanted tumors in both groups secondary to OIS. It was noted that the levels of transformation related protein 53 (Trp53), a tumor suppressor gene, increased in tumors undergoing OIS regression, and Trp53 deactivation reversed OIS and enabled tumor growth with the characteristics of ATC (i.e. transformation of PTC to ATC tumor cells). BRAF-induced PTC could be regulated via a p53-dependent mechanism, however both OIS and TSH seemed to cause major disruption of this mechanism. Zou et al. therefore stressed the importance of controlling serum TSH in PTC patients.

Furthermore, cells undergoing OIS interact mainly with CXCR2 along with CCL20, IL-8 and IL-6, and knockdown of either CXCR2 or IL-8 can lead to a reduction in OIS and re-proliferation of tumor cells (99). Therefore, increasing the CXCR2/IL-8 complex could be used as a potential therapeutic target to promote the arrest of cellular growth and eventually delay the early onset of tumorigenesis (99).
Use as clinical biomarkers:

CXCL8 (IL8) and its receptor CXCR2 are increased in MTC with higher levels in patients with lymph node metastases (105-107). Sunitinib is a multi-kinase inhibitor with both anti-angiogenic and anti-tumoral activities (107). Broutin et al. (107) demonstrated that the CXCL8 gene displayed major changes during sunitinib treatment both in vivo and in vitro indicating that secreted CXCL8 can be used as a biomarker of favorable clinical response to sunitinib. Administration of the drug to tumor-inoculated mice reduced tumor growth and angiogenesis but also significantly decreased the serum concentration of CXCL8.

Resistance to the drug was countered by administering CXCL8 neutralizing antibody, which re-sensitized the tumor to it, thus indicating that CXCR8 is a useful positive biomarker and a therapeutic target of sunitinib. As mast cells are increased in PTC and their abundance is positively correlated with tumor growth, survival and invasiveness, monitoring the density of mast cells could be used as a clinical biomarker of tumor progression and targeted blocking of chemokine CXCL1 and CXCL10 pathways may be of therapeutic benefit in the future.

Conclusion

It is evident that research during the last three decades has found multiple links between the chemokine system and cancer as our understanding of the complex signaling pathways has developed. Chemokines and their receptors are involved in every stage of thyroid cancer development, from control of the tumor cellular microenvironment to malignant cell survival and metastatic spread. Cancer cells are known to alter the chemokine system, that under normal circumstances enable healthy embryonic development, homeostasis and successful immune responses to a pathogen. With further research it may be possible to identify common chemokine markers and pathways by blood or tissue testing, which may have the potential to further characterize and treat some forms of thyroid carcinomas and prevent metastatic progression.
Disclosure statement: The authors have nothing to disclose

Name and address of corresponding author:

Miss Sharinie Yapa

Department of Otolaryngology and Head and Neck Surgery, Castle Hill Hospital, Hull, HU16 5JQ, United Kingdom

Email: sharinie@gmail.com

Tel: +447935926964
References:

1. National Cancer Institute. Surveillance, Epidemiology and End Results Program. SEER Stat Factsheet: Thyroid Cancer. Available at http://seer.cancer.gov/statfacts/html/thyro.html accessed July 25, 2017

2. Balkwill F R 2012 The Chemokine system and Cancer. Journal of Pathology 226: 148-157

3. Zlotnik A, Yoshie O 2000 Chemokines: A new classification system and their role in immunity. Immunity 12: 121-127.

4. Kakinuma T, Hwang T S 2006. Chemokines, chemokine receptors and cancer metastasis. Journal of leukocyte biology 79: 639 – 651.

5. Allaventa P, Germano, G Marchesi F, Mantovani A 2011 Chemokines in cancer related inflammation. Exp Cell Res 317:664-673.

6. Mantovani A, Savino B, Zammataro L, Allavena P, Bonecchi E 2010 The Chemokine system in cancer biology and therapy. Cytokine growth Factor Rev 21: 27-29.

7. Fernandez E J, Lolis E 2002 Structure, function and inhibition of chemokines. Annual review of pharmacology and toxicology 42; 469-499.

8. Mukaida N, Sasaki S, Baba T 2014 Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.
9. Zlotnik A, Burkhardt A M, Homey B 2011 Homeostatic chemokine receptors and organ specific metastasis. *Nat Rev Immunology* 11: 597-606.

10. Di Liberto D, Locati M, Caccamo N, Vecchi A, Meraviglia S, Salerno A, Sereci G, Nebuloni M, Caceres N, Cardon P J, Dieli F, Mantovani A 2008 The atypical chemokine receptor D6 in balancing inflammation, immune activation and antimicrobial resistance in mycobacterium tuberculosis infection. *Journal of Exp Med* 205: 2075-2084.

11. Nibbs R J, Gilchrist D S, King V, Ferra A, Forrow S, Hunter K D, Graham G J 2007 The atypical chemokine receptor D6 supresses the development of chemically induced skin tumours. *Journal of Clin Invest* 117: 1884-1892.

12. Balkwill F 2004 Cancer and the chemokine network. *Nat Rev Cancer* 4:540-550.

13. Aldinucci D, Gloghini A, Pinto A, De Fillipi R, Carribone A 2010 The classical Hodgkins lymphoma microenvironment and its role in promoting tumour growth and immune escape. *Journal of Pathology* 2010. 3: 248 – 263.

14. Meadows S A, Vega F, Kashishian A, Johnson D, Diehl V, Miller L L, Younes A A, Lanutti B J 2012 P13K alpha inhibitor GS-1101 (CAL 101), attenuates pathway signaling, induces apoptosis and overcomes signals from the microenvironment in cellular models of hodgkins lymphoma. *Blood* 119 (8):1897 – 1900.
15. Balkwill F 2004 The significance of cancer cell expression of CXCR4. Semin Cancer Biol 14: 171-179.

16. Zlotnik A, Burkhart A M, Homey B 2011 Homeostatic chemokine receptors and organ specific metastasis. Nat Rev Immunology 11: 597-606.

17. Fugazzola L, Colombo C, Perrino M, Muzza M 2011 Papillary thyroid carcinoma and inflammation. Front Endocrinol; 2 (88) doi:10.3389/fendo.2011.00088.

18. Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, Latteri S, Latteri M A 2005 Hashimotos Thyroiditis co existant with papillary thyroid carcinoma 71: 874-875.

19. Mantovani A, Allaventa P, Sica A, Balkwill S 2008 Cancer related inflammation. Nature 454: 436-444.

20. Sica A, Allaventa P, Mantovani A 2008 Cancer related inflammation: The macrophage connection. Cancer Lett 267:204 – 215.

21. Yoshida M, Matsuzaki H, Sakata K, Takeya M, Kato K, Mizushima S 1992 Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma. Cancer Res 52: 464-469.

22. Weetman A P, Bennet G L, Wong W L 1992 Thyroid follicular cells produce interleukin 8. Journal of clinical endocrinology and metabolism 75:328-330.

23. Basolo F, Giannini R, TonioloA, Casalone R, Nikiforova M, Pacini E, Elisei R, Miccoli P, Berti P, Faviana P, Fiore L, Monaco C, Pierantoni G M, Fedele M, Nikiforov Y E,
Santoro M, Fusco M 2002 Establishment of no tumergenic papillary thyroid cell line FB-2 carrying the RET/PTC1 rearrangement. Int Journal of Cancer 97:608-614.

24. Kobawala T P, Patel G H, Gajjar D R, Patel K N, Thakor P B, Parekh U B 2011 Clinical utility of serum interleukin-8 and interferon alfa in thyroid diseases. J Thyroid Res 2011:270149.

25. Greaves D R, Wang W, Dairaghi D J Dieu M C, Saint Vis B, Franz Bacon K, Rossi D, Caux C, Macallahan T, Gordon S, Zlotnik A, Schall T J 1997 CCR6 a CC chemokine receptor that interacts with macrophage inflammatory protein 3 alpha and is highly expressed in human dendritic cells. J of Exp Med 186:837-844.

26. Zeng W, Chang H, Ma, M, Yanwei L 2014 CCL20/ CCL6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling- induced MMP-3 production. Exp and Mol Pathology 97:184-190.

27. Dellegrottaglie S, Sanz S, Rajagopalan S 2006 Molecular determinants of vascular calcification: A bench to bedside view. Curr Mol Med 6:515-524.

28. Borrello M G, Alberti L, Fischer, Degl’innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavera P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA 2005 Induction of a pro inflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825-14830.

29. Hwang Jung Hwan, Hwang Jin Hee, Chung H K, Wook Kim D, Hwang E S, Suh J M, Kim H, You K H, Kwon O Y, Ro H K, Jo D Y, Shong M 2003 CXC chemokine receptor 4...
expression and function on human Anaplastic thyroid Cancer cells. The Journal of Clinical Endocrinology and Metabolism 88: 408- 416.

30. Wagner P L, Moo T A, Arora N, Liu Y, Zarnegar R, Scognamigilio T, Fahey T 2008 The chemokine receptors CXCR4 and CCR7 are associated with tumour size and pathological indicators of tumour aggressiveness in papillary thyroid carcinoma. *Annals of surgical oncology* 15:2833- 2841.

31. Castellone M D, Guarino V, De Falco V 2004 Functional expression of CXCR4 chemokine receptor is induced by RET/ PTC oncogenes and is a common event in human papillary thyroid carcinomas. *Oncogene* 23: 5959- 5967.

32. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanbe S 1997 Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. *Cancer* 80: 2268- 2272.

33. Sancho M, Vieira J M, Casalou C, Mesquita M, Pereira T, Cavaco B M, Dias S, Liete V 2006 Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. *Journal of endocrinology* 191: 229- 238.

34. Frick V O, Rubie C, Kolsch K, Wagner M, Gadhar P, Greaber S, Glanemann M 2013 CCR6/ CCL20 chemokine expression profile in distinct colorectal malignancies. *Scand J of Immunology* 78: 298- 305.

35. Rubie C, Frick V O, Ghadjar P, Wagner M, Grimm H, Vicinus B, Justinger C, Greaber S, Schilling M K 2010 CCL20/ CCL6 expression profile in pancreatic cancer. *J of Translational Med* 8:45.
36. Kirshberg S, Izhar U, Amir G, Demma J, Vernae F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira O M, Peled A, Wald O 2011 Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. Plos One 6: e24856.

37. DingX, Wang K, Wang H, Zhang H, Liu Y, Yang Q, Chen W, Hu S 2012 High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J of Gastrointestinal Surg 16: 828- 836.

38. Fuji H, Itoh Y, Yamaguchi K, Yamauchi K, Harano Y, Nakajima T, Minami M, Okanoue T 2004 Chemokine CCL20 enhances the growth of HuH7 cells via the phosphorylation of p44/42 MAPK in vitro. Biochem Biophys Res Commun 322:1052- 1058.

39. Rotondi M, Coperchini F, Chiovato L 2013 CXCL8 in thyroid disease: From basic notions to potential applications in clinical practice. Cytokine and growth factors 23: 539 – 546.

40. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S 2004 CXC chemokines, the regulatory link between inflammation and angiogenesis. Trends Immunology 25:201-209.

41. Weiyuan F, Lei Y, Shen L, Kai J, Huang F, Wei Q, Fei X, Chen X, Guan H, Wang W, Li X, Ning G 2014 Tumour associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 35: 1780-1787.

42. Cho S W, Kim Y, Sun H, Kim Y, Oh B, Yi K, Park D, Park Y 2015 CXCL16 mediated macrophage effects on tumour invasion of papillary carcinoma. Endocrin Relat
Canc 23:113-124.

43. Quian B Z, Polland J 2010 Macrophage diversity enhances tumour progression and metastasis. Cell 141: 39- 51.

44. Polland J W 2004 Tumour educated macrophages promote tumour progression and metastasis. Cell 4: 71- 78.

45. Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q, Fei X, Chen X, Guan H, Wang W, Li X, Ning G 2014 Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 35:1780-1787.

46. Qing W et al, Fang W Y, Ye L, Shen L Y, Xang X F, Fei X C, Chen X, Wang W Q, Li X Y, Xiao J C, Ning G 2012 Density of tumour associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 22: 905- 910.

47. Mantovani A, Souzzani S, Locati M, Allavena P, Sica A 2002 Macrophage polarization: tumour associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology 23:549-555.

48. Cunha LL, Marcello M A, Ward L S 2014 The role of inflammatory microenvironment in thyroid carcinogenesis. Endocrine related cancer 21: R85-R103.

49. Ryder M, Ghossein R A, Ricarte Filho J C, Knauf J A, Fagin J A 2008 Increased density of tumour associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine related cancer 15: 1069-1074.
50. Fiumara A, Belfiore A, Russo G, Salomone E, Santoncito G M, Ippolito O, Riccardo Vigneri, Pietro Gangemi 1997 In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid carcinoma. J of clin endocrinology and metabolism 82: 1615-1620.

51. Melillo R M, Guarino V, Avilla E 2010 Mast Cells have a Protumerogenic role in Human Thyroid Cancer. Oncogene 29: 6203- 6215.

52. Teicher B A, Fricker S P 2010 CXCL12 (SDF-1)/ CXCR4 pathway in cancer. Clin Cancer Res 16: 2927- 2931.

53. Kim C H, Brxmeyer H E 1999 SLC/ exodus/ 6CKine/ TCA4 induces chemotaxis of haemopoeitic progenitor cells differential action of ligands of CCR7, CXCR3 or CXCR4 in chemotaxis vs suppression of progenitor proliferation. Journal of Leuk Biology 66: 455- 461.

54. Aiuti A, Tavian M, Cipponi A, Ficara F, Zappone, E., Hoxie, J., Peault, B. and Bordignon, C 1999 Expression of CXCR4, the receptor for stromal derived factor-1 on fetal and adult human lympho-haemopoietic progenitors. European Journal Immunology 29: 1823- 1831.

55. Spano J P, Andre F, Morat L Sabatier, L., Besse, B., Combadiere, C., Deterre, P., Martin, A., Azorin, J., Valeyre, D. and Khayat, D 2004 Chemokine receptor CXCR4 and early stage non small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncology 15: 613- 17.
56. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, Xiong S 2005 Differential expression of CXCR4 is associated with metastatic potential of non small cell lung cancer cells. Clin Cancer Res 11: 8273-80.

57. Salvuccis O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M 2006 The Role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast cancer Res Treat 97: 275-83.

58. Akashi T, Koizunmi K, Tsoneyama K, Saiki I, Takano Y, Fuse H 2008 Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Science 99:539-542.

59. Kim J, Takeuchi H, Lam S T, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS 2005 Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncology 23: 2744-53.

60. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanbe S 1997 Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 80: 2268-2272.

61. Yamashita H, Noguchi S, Murakami N, Toda M, Uchino S, Watanbe S, Kawamoto H 1999 Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 86: 842-849.

62. Zhen L, Sun DX, Teng XY, Xu WX, Meng XP, Wang BS 2012 Expression of stromal derived factor – 1 and CXCR7 in papillary thyroid carcinoma. Endocrine Pathology 23: 247-253.
63. Tang C, Yang L, Wang N, Li L, Chen G, Liu Z 2014 High expression of GPER1 and EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma. *Int J Clin Exp Pathology* 7:3213-3223.

64. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S 2008 Functions of natural killer cells. *Nature Immunology* 9: 503-510.

65. Walzer T, Vivier E 2011 G protein coupled receptors in control of natural killer cell migration. *Trends in Immunology* 32: 486-492.

66. Gogaldi F, Paterakis G, Kaltsas G, Liakou C I, Gousis P, Neonakis E Manoussakis M N, Liapi C 2012 Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in papillary carcinoma thyroid. *Journal of clinical endocrinology and metabolism* 97: 1474-1482.

67. Wennerberg E, Pferfferie A, Ekblad L, Yoshimoto Y, Kremer V, Kaninsky V O, Juhlin C C, Hoog A, Bodin I, Svjatoha V, Larsson C 2014 Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. *Clinical Cancer Res* 20: 5733-44.

68. Melillo R M, Castellone M D, Guarino V, De Falco V, Cirafici A M, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T 2005 The RET/PTC- RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. *J Clin Invest* 115: 1068-1081.

69. Puxeddu E, Knauf J A, Sartor M A, Mitsutake N, Smith E P, Medvedovic M, Tomlinson CR, Moretti S, Fagin JA 2005 RET/PTC induced gene expression in thyroid
PCCL3 cells reveals early activation of genes involved in the regulation of the immune response. Endocrine Related Cancer 12: 319-314.

70. Mc Call K D, Harii N, Lewis C J, Malgor R, Kim W B, Saji M, Kohn AD, Moon RT, Kohn LD 2007 High basal levels of functional toll like receptor 3 (TLR3) and noncanonical WnSa are expressed in papillary carcinoma thyroid and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 148: 4226-4237.

71. Antonelli A, Ferrari S M, Fallahi P, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F 2009 Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator activated receptor gamma agonists. Endocrine related Cancer 16: 1299-1311.

72. Liu M, Guo S, Stiles J 2011 The emerging role of CXCL10 in cancer. Oncology Letters 2: 583-589.

73. Persano L, Crescenzi M and Indraccolo S 2007 Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28: 87-114.

74. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM 2000 CXC chemokines in angiogenesis. J Leukoc Biol 68: 1-8.

75. Antonelli A, Ferarri S M, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, Santarpia L, Basolo F, Ferrarinii E, Miccoli P 2012 Variable modulation by cytokines and thzolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine 59: 218-222.
76. Latini FRM, Bastos AU, Arnoni CP, Muniz JG, Person RM, Baleotti W, Barreto JA, Castilho L, Cerutti JM 2013 DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer. Blood Cells, Mol Dis 50: 161- 165.

77. Mantovani A, Bonecci R, Locati M 2006 Turning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunology 6:907.

78. Zeng XH, Ou ZL, Yu KD, Feng LY, Yin WJ, Li J, Shen ZZ, Shao ZM 2011 Coexpression of atypical chemokine binders (ABCs) in breast cancer predicts better outcomes. Breast cancer Res Treat 125: 715- 727.

79. Wang J, Ou ZL, Hou YF, Luo JM, Chen Y, Zhou J, Shen ZZ, Ding J, Shao ZM 2005 Duffy antigen receptor for chemokines attenuates breast cancer growth and metastasis: an experiment with nude mice. Zhonghua Yi Xue Za Zhi 85: 2033- 2037.

80. Addison CL, Belperio JA, Burdick R M, Strieter RM 2004 Overexpression of the Duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumour necrosis. BMC Cancer 4:28.

81. Sun G, Wang Y, Zhu Y, Huang C, Ji Q 2011 Duffy antigen receptor for chemokines in laryngeal squamous cell carcinoma as a negative regulator. Acta Otolaryngol 131: 197- 203.

82. Modi J, Patel A, Terrel R, Tuttle RM, Francis G 2003 Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. Journal of clinical endocrinology and metabolism 88:4418- 4425.
83. French J D, Kotnis G, Daid S, Klopper J, Hauggen 2010 B Tumour associated lymphocytes increased FoxP3c regulatory T cell frequently correlate with more aggressive papillary thyroid cancer. *Journal of clinical endocrinology and metabolism* 95: 2325-2333.

84. Pan J, Burdick JA, Belperio, Xue YY, Gerard C, Sharma S, Dubinett SM, Strieter RM 2006 CXCR3/ CXCR3 ligand biological axis impairs RENCA tumour growth by a mechanism of immunoangiostasis. *Journal of immunology* 176: 1456-1464.

85. Facciabene A, Peng X, Hagemann I, Balint K, Wang L, Gimmoty P, Glikis B, Lal P, Zhang L, Coukos G 2012 Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells. *Immunology* 137: 622.

86. Villagelin DG, Santos RB, Romaldini JH 2011 Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis? *Journal of Endocrinological Investigation* 34: e403-e408.

87. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K, Tamai H 1995 The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. *Journal of clinical endocrinology and metabolism* 80: 3421-3424.

88. Gupta S, Patel A, Folstad A Fenton C, Dinauer CA, Tuttle RM, Conran RM and Francis GL 2001 Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes associated with improved disease free survival for children and young adults. *Journal of clinical endocrinology and metabolism* 86: 1346-1354.
89. Fusco A, Grieco M, Santoro M, Berlingieri M T, Pilotti S, Pierotti M A, Della Porta G, Vecchio G 1987 A new oncogene in human thyroid papillary carcinoma and their lymph nodal metastasis. *Nature* 328: 170-172.

90. Grieco M, Santoro M, Berlingieri M T, Melillo R M, Donghi R, Bongarzone I, Pierotti M A, Delaa Porta G, Fusco A, Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinoma. *Cell* 60: 557-563.

91. Xing M. BRAF mutation in thyroid cancer 2005 *Endocrine Related Cancer* 12: 245-262.

92. Burns JM, Summers BC, Wang Y, Melikian A, Beratovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K 2006 A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion and tumour development. *Journal of experimental medicine* 203:2201-2213.

93. Muzza M, Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck Peccoz P, Borrelli M, Fugazzola L 2010 The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. *Clin Endocrinology* 72: 702-708.

94. Torregrossa L, Giannini N, Borrelli N, Sensi E, Melillo RM, Leocata P, Materazzi G, Miccoli P, Santoro M, Basolo F 2012 CXCR4 expression correlates with the degree of tumour infiltration and BRAF status in papillary thyroid carcinomas. *Modern Pathology* 25: 46.
95. Sharma S, Stolina, L, Zhu Lin Y, Batra R, Huang M, Strieter R, Dubinett SM 2001 Secondary lymphoid organ chemokine reduces pulmonary tumour burden in spontaneous murine bronchoalveolar cell carcinoma. *Cancer Research* 61: 6406-6412.

96. Fidler J, Ellis LM 1994 The implications of angiogenesis for the biology and therapy of cancer metastasis. *Cell* 79: 678-689.

97. Kuilman T, Michaloglou C, Mooi W 2010 Oncogene induced senescence. *Genes and Development* 24: 2463-2479.

98. Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al Ghuzlan A, Bidart JM, Schlumberger M 2012 ROS– generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras induced DNA damage and subsequent senescence. *Oncogene* 31: 1117-1129.

99. Vizioli M G, Santos J, Pilotti S, Mazzoni M, Anania AM, Miranda C, Pagliardini S, Pierotti M A, Gil J, Greco A 2014 Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved. *Oncotarget* 5:8270.

100. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R 2008 *BRAFV600E*mutation, but not *RET/PTC* rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. *Endocr Relat Cancer* 15:511–520.

101. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E 2007 *BRAF* mutations in papillary thyroid carcinomas
inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92: 2840–2843.

102. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H 2009 Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 71:434-439.

103. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA 2006 Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91: 4295–4301.

104. M Zou, E Y Baitei, R A Al-Rijjal, R S Parhar, F A Al-Mohanna, S Kimura, C Pritchard, H A Binessa, A S Alzahrani, H H Al-Khalaf, A Hawwari, M Akhtar, A M Assiri, B F Meyer and Y Shi 2016 TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. Oncogene 35: 1909-15.

105. Teichmer T, Dlott J, Chuntharapai A, Martin AW, Peiper SC 2000 Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells. Arch Path Lab Med 124: 520- 525.

106. Aust G, Stienert M, Boltz C, Kiessling S, Simchen C 2001 GRO alpha in normal and pathological thyroid tissue and its regulation in thyroid derived cells. J Endocrinol 170: 513-20.

107. Broutin S, Ameur N, Lacroix L, Robert T, Petit B, Oumata N, albot M, Caillou B, Schlumberger M, Dupuy C, Bidart JM 2011 Identification of soluble candidate
biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res 17: 2044-2054.

108. Aust G, Steinert M, Keissling S, Kamprad M, Simchen C 2001 Reduced expression of stromal derived factor-1 in autonomous thyroid adenomas and its regulation in thyroid derived cells. J Clin Endocrinology Metab 86: 3368-76.

109. De Falco V, Guarino, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M, Melillo RM 2007 Biological role and potential therapeutic targeting of chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67: 11821-9.

110. Zhen L, Lei Y, Teng, X., Zhang, H. and Guan, H 2014 The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma. Journal of Surgical Research 191: 379-388.

111. Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S 2014 CLM3, a Multitarget Tyrosine Kinase Inhibitor with Antiangiogenic Properties is active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. Journal of Endocrinology and Metabolism 99: 572-581.

112. Antonelli A, Fallahi P Ulisse S, Martina Ferrari S, Minuto M, Saraceno G, Santini F, Mazzi V, D’Armiento M, Miccoli P 2012 New Targeted therapies for Anaplastic Thyroid Cancer. Anticancer Agents Med Chem 12: 87-93.

113. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P 2007 New trends in the treatment of undifferentiated carcinomas of thyroid. Langenbecks Arch Surg 392: 397-404.
114. Are C, Shaha A R 2006 Anaplastic Thyroid Carcinoma: Biology, pathogenesis, prognostic factors and treatment approaches. Ann Surg Oncology 13: 453-464.

115. Ain KB 1999 Anaplastic Thyroid Carcinoma: A Therapeutic Challenge. Semin Surg Oncology 16: 64-69.

116. Neff RL, Farrar WB, Kloos RT, Burman KD 2008 Anaplastic Thyroid Cancer. Endocrinology Metabolism Clin North Am 37: 525-538.

117. Wartofsky L 2009 Highlights of the American Thyroid Association Guidelines for Management of Thyroid Nodules and Thyroid Cancer: The 2009 Revision; Thyroid 19: 1139-1143.

118. De Crevoisier R, Boudin, Bachelot 2004 Combined treatment for Anaplastic Thyroid Cancer with Surgery, Chemotherapy and Hyperfractionated Accelerated External Radiotherapy. Int Journal Oncology Biology Physics 60: 1137-1143.

119. Vertrano S, Borroni E M, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, Fantini M, Roncalli M, Malesci A, Mantovani A 2009 The lymphatic system controls intestinal inflammation and inflammation associated colon cancer through the chemokine decoy receptor D6. Gut 59: 222-225.

120. Aldenucci D, Colombatti A 2014 The inflammatory chemokine CCLS and cancer progression. Mediators of Inflammation 8: 292-376.
121. Ben – Baruch A 2012 The tumour promoting flow of cells into, within and out of the tumour site: regulation by the inflammatory axis of TNF alpha and chemokines 5: 151-164.

122. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA 2007 Mesenchymal stem cells within the tumour stoma to promote breast cancer metastasis. Nature 449:557-563.

123. Rahman D, Sobolik-Delmaire T, Richmond A 2011 Chemokines in health and disease. Exp Cell Res 317:575 – 589.

124. Ryder M, Gild M, Hohl T M, Pamer E, Knauf J A, Ghossien R, Joyce A, Fagin J A 2013 Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumour associated macrophages and impairs BRAF induced thyroid carcinoma progression PloS one 8: e54302.

125. Lazeennec G, Richmond A 2010 Chemokines and chemokine receptors: new insights into cancer related inflammation. Trends in molecular medicine 16:133-144.

126. Nishikawa H, Sakaguchi 2010 Regulatory T cells in tumour immunity. International journal of cancer 127: 759-767.

127. Knutson K L, Disis L 2008 Tumour antigen specific T helper cells in cancer immunity and immunotherapy. Cancer immunology and immunotherapy 54:721-728.

128. Paluka K, Banchereau 2012 Cancer immunotherapy via dendritic cells. Nature reviews cancer 12:265-277.
129. Ohad Hilly MD, Rumelia Koren MD, Raanan Raz PhD, Lea Rath-Wolfson MD, Aviram Mizrachi MD, Yaniv Hamzany MD, Gideon Bachar MD, Thomas Shpitzer MD 2013 The Role of S100-Positive Dendritic Cells in the Prognosis of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology 139:87-92.

130. Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, Chen X, Wang WQ, Li XY, Xiao JC, Ning G 2012 Density of tumor associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 22: 905-910.

131. Keeley E C, Mehrad B, Strieter R M 2011 Chemokines as mediators of tumor angiogenesis and neovascularization. Experimental Cell Research 317: 685-690.

132. Du J, Luan J, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A 2002 Potential role for Duffy antigen chemokine binding protein in angiogenesis and maintenance of homeostasis in response to stress. Journal of Leukocyte Biology 71:141-153.

133. Allen S J, Crowne S E, Handel T M 2007 Chemokine: Receptor, structure, interactions and antagonism. Ann Rev Immun 25:787-820.

134. Neel N F, Schuttyser E, Sai J, Fan GH Richmond A 2005 Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev 16: 637-658.

135. New D C, Wong Y H 2003 CC chemokine receptor coupled signaling pathways. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35:779-788.
136. Zimmerman N, Conkright JJ, Rothenberg ME 1999 CC chemokine receptor-3 undergoes prolonged ligand induced internalization. *J of Biol Chem* 274: 12611-12618.

137. Beaulieu S, Robbiani D F, Du X, Rodrigues E, Ignatius R, Wei W, Ponath P, Young J W, Pope M, Stienman R M, Mojsov S 2002 Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells. *J of Immunology* 169:2925-2936.

138. Forster R, Kremmer E, Schubel A, Brietfield D, Kleinshidt A, Nerl C, Bernhardt G, Lipp M 1998 Intracellular and surface expression of the HIV co-receptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling on activation. *J of Immunology* 160:1522-1533.

139. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene RET by DNA rearrangement. *Cell* 42: 581-588.

140. Russell J P, Shinohara S, Melillo R M, Castellone M D, Santoro M, Rothstein J L 2003 Tyrosine kinase oncoprotein RET/PTC3 induces the secretion of myeloid growth and chemotactic factors. *Oncogene* 22:4569-4577.

141. Acosta J C, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y 2008 Chemokine signalling via the CXCR2 receptor reinforces senescence. *Cell* 133:1006-1018.
| Chemokine Name | Effects | Reference |
|---------------|---------|----------|
| GRO-α         | Chemotaxis, Tumor Growth | 22, 31, 32, 33 |
| GRO-β         | Tumor Growth, Invasion of Tumor Cells | 22, 31, 32, 33 |
| GRO-γ         | -       | 4, 21, 22, 23, 24, 25 |
| CCL-3         | Chemotaxis, Tumor Growth | 22, 31, 32, 33 |
| CCL-4         | -       | 4, 21, 22, 23, 24, 25 |
| CCL-5         | -       | 4, 21, 22, 23, 24, 25 |
| CCL-7         | -       | 4, 21, 22, 23, 24, 25 |
| CCL-11        | -       | 4, 21, 22, 23, 24, 25 |
| CCL-13        | -       | 4, 21, 22, 23, 24, 25 |
| CCL-24        | -       | 4, 21, 22, 23, 24, 25 |

**Key:**
- Ba: basophil
- Eo: eosinophil
- iDC: immature dendritic cell
- mDC: mature dendritic cell
- NK: natural killer cell
- Th1: type I helper cell
- Th2: type II helper cell
- Treg: regulatory T cell
- PTC: Papillary thyroid carcinoma
- ATC: Anaplastic thyroid carcinoma
- MTC: Medullary thyroid carcinoma
- FTCA: Follicular thyroid carcinoma
- LNM: Lymph node metastasis

**Table 1:** Chemokines associated with Thyroid Carcinoma and their effects.
Figure 1: Structure of chemokine subtypes

Chemokines are divided into four subtypes: C, CC, CXC and CX3C.

The CC chemokines are the most abundant group having two adjacent cysteines near their amino terminus. They principally induce the migration of monocytes, NK cells and dendritic cells. CXC chemokines have N-terminal cysteines that are separated by one amino acid, represented in their name with an "X". CXC chemokines are the next most abundant group, and are subdivided into two categories: ELR-positive, and ELR-negative. ELR-positive CXC chemokines specifically induce the migration of neutrophils, and interact with chemokine receptors CXCR1 and CXCR2.
C chemokines only have two cysteines and there are only two chemokines in this subgroup, XCL1 and XCL2, which activate and attract T cells respectively. CX3C chemokines have three amino acids between the two cysteines. The only one discovered to date is CX3CL1, which is secreted and attached to the surface of the cell that expresses it, serving as a chemoattractant and adhesion molecule.
Figure 2: Diagram of a chemokine receptor

Each chemokine receptor comprises of an extracellular N terminal, seven transmembrane proteins, three extracellular loops, three intracellular loops, a characteristic “DRY” motif in the second intracellular domain and a C-terminal segment. These seven transmembrane proteins couple with a “G protein” making them members of a large protein family known as the G protein (guanine nucleotide binding proteins) coupled receptors. Transmembrane proteins span the entire length of the biological membrane to which they are permanently attached and function as a transporter of various substances across the membrane. G proteins; function as molecular switches, which transmit signals from the extracellular environment to the intracellular environment. These proteins are activated by the highly conserved “DRY” motif following binding with the corresponding chemokine ligands, which triggers an influx of intracellular calcium. This induces chemotaxis that acts to drive cells to a desired location within the organism.
Figure 3: The Chemokine Wheel

This diagram shows the major features of the chemokine system, chemokine receptors and their associated chemokine ligands. The inflammatory chemokines are frequently involved with routine immune responses whereas the homeostatic group contributes to normal development and physiology. The atypical or “silent” receptors act as negative regulators of the system, which decrease the levels of chemokines. Viral chemokines and receptors allow pathogens to change immune responses to infection. Only the inflammatory, homeostatic and atypical chemokine receptors are found within the thyroid microenvironment. This diagram is reproduced with permission from Wiley and Sons 2016.
Figure 4: Immune cells involved in anti or pro-tumour responses

Pro-tumorigenic cells include M2 macrophages, certain lymphocytes, NK cells, mast cells and neutrophils. Anti-tumorigenic cells include M1 macrophages, certain lymphocytes and dendritic cells. The balance of anti/pro-tumorigenic responses may be important for thyroid cancer progression or elimination. Diagram reproduced with licensing permission from Bioscientifica Ltd 2016
Figure 5: Schematic diagram showing a possible order of sequential stages in tumour development with the associated pro-tumorigenic chemokines and receptors involved at each step within the tumour microenvironment identified.